In a 78-week clinical trial for assessing the efficacy and safety of adding empagliflozin to basal insulin therapy in patients with poorly controlled T2D, individuals were randomly assigned to different doses of empagliflozin (10mg or 25 mg) or a placebo group. Here, INS is linked to type 2 diabetes mellitus.